Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations

Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmana J, Fasching P, Hurvitz SA, Albacker LA, Frampton GM, Chelliserry J, Bycott P, Conte U, Wardley AM, Robson ME (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Annals of Oncology Elsevier

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Pages Range: 108-+

Conference Proceedings Title: ANNALS OF ONCOLOGY

Event location: Barcelona

DOI: 10.1093/annonc/mdz242.009

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Memorial Sloan Kettering Cancer Center

United States (USA) (US) Foundation Medicine

United States (USA) (US) University of Manchester

United Kingdom (GB) Pfizer, Inc.

United States (USA) (US) UCSF Helen Diller Family Comprehensive Cancer Center

United States (USA) (US) Royal Marsden Hospital / The Royal Marsden NHS Foundation Trust

United Kingdom (GB) Banner MD Anderson Cancer Center

United States (USA) (US) Autonomous University of Barcelona (UAB) / Universitat Autònoma de Barcelona

Spain (ES) University of California Los Angeles (UCLA)

United States (USA) (US) Centre Oscar Lambret (UNICANCER)

France (FR) Eberhard Karls Universität Tübingen

Germany (DE) Technische Universität München (TUM)

Germany (DE) Stanford University

United States (USA) (US)

How to cite

APA:

Turner, N.C., Laird, A.D., Telli, M.L., Rugo, H.S., Mailliez, A., Ettl, J.,... Robson, M.E. (2019). Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations. In ANNALS OF ONCOLOGY (pp. 108-+). Barcelona, ES: OXFORD: OXFORD UNIV PRESS.

MLA:

Turner, N. C., et al. "Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations." Proceedings of the 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona OXFORD: OXFORD UNIV PRESS, 2019. 108-+.

BibTeX: Download